This study aims to evaluate the efficacy of prophylactic ruxolitinib in adult patients at intermediate-to-high risk of severe acute GvHD, as predicted by the daGOAT model.
Age > 16 years old.
HLA-haploidentical transplant.
Able to take oral medications.
Patients must provide written informed consent before the start of the study procedures.
Patients who have undergone tandem transplantation or multiple transplantations.
Patients who are allergic to or cannot tolerate ruxolitinib.
Patients with mental or other medical conditions that make them unable to comply with the study treatment and monitoring requirements.
Patients who are ineligible for the study due to other factors, or who will bear great risk if they participate in the study.